Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042796 · ClinicalTrials.gov registry record · Phase 1
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00042796: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00042796 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00042796, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of decitabine in treating children with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2002-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042796
The ClinicalTrials.gov registry entry for NCT00042796 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00042796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00042796 about?
NCT00042796 is a clinical study titled "Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia". Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of decitabine in treating children with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia
What is the current status of trial NCT00042796?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2002-12.
What interventions are being tested in trial NCT00042796?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), decitabine (DRUG).
Who is sponsoring clinical trial NCT00042796?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.